
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
For Contemporary Pediatrics, Dr Bobby Lazzara explains an abstract presented at the European Respiratory Society International Congress that examined whether early antibiotic exposure increases the risk of allergic rhinitis.
For Contemporary Pediatrics, Dr Bobby Lazzara explains an abstract presented at the European Respiratory Society International Congress that examined whether early antibiotic exposure increases the risk of allergic rhinitis.






